focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Rise On "Constructive" US-China Talks

Mon, 18th Nov 2019 11:59

(Alliance News) - Stocks in London were higher at midday on Monday on hopes of a resolution in the protracted trade war between the US and China and following a positive close in Asian equity markets.

Top Chinese and US trade negotiators held "constructive" discussions over the phone on a preliminary trade deal between the two countries, China's commerce ministry said in a statement on Sunday.

US President Trump announced a "phase one" trade deal in October which has yet to be signed. Vice Premier Liu He spoke with US Trade Representative Robert Lighthizer and Treasury Secretary Steven Mnuchin on Saturday, and had "constructive discussion on each side's core concerns regarding the phase-one agreement", the Chinese commerce ministry said.

The two sides will "continue to maintain close communication", it added, without providing further details.

The UK large-cap index was up 8.21 points, or 0.1%, at 7,311.15. The FTSE 250 was up 75.62 points, or 0.4%, at 20,480.02, and the AIM All-Share was up 2.91 points, or 0.3% at 895.21.

The Cboe UK 100 index was up 0.2% at 12,387.62. The Cboe UK 250 was up 0.7% at 18,425.07 and the Cboe UK Small Companies was up 0.1% at 11,289.71.

"Markets are following their Asian counterparts higher this morning, as positive tones from China helped set stocks on an upward trajectory. A weekend call between Steve Mnuchin, Robert Lighthizer, and Chinese Vice Premier Liu He resulted in 'constructive talks' according to Chinese reports. With the phase one deal previously expected to be signed this week in a now cancelled summit in Santiago, there is still a belief that we are approaching a partial deal that could provide the kind of positivity that markets have already been showing amid record highs in the US," said IG Group's Josh Mahony.

The Japanese Nikkei 225 index closed 0.5% higher on Monday. In China, the Shanghai Composite ended up 0.6%, while the Hang Seng index in Hong Kong closed up 1.4%.

Stocks in New York were set for a higher open, with the DJIA was called up 0.2%, the S&P 500 index up 0.1% and the Nasdaq Composite up 0.2%, having closed at fresh record highs on Friday. The Dow finished above the 28,000 mark for the first time on Friday.

In Paris the CAC 40 and the DAX 30 in Frankfurt were both down 0.3%.

In the FTSE 100, Aviva was the worst performer, down 4.2% after the insurer decided to retain its Singapore businesses.

Aviva said the move follows a "thorough" review of options for the Singapore business, including seeking offers for the business. Earlier on Monday, Bloomberg reported that Japan's MS&AD Insurance Group Holdings and Canada's Manulife Financial Corp were vying to buy Aviva's assets in Singapore and Vietnam, with the sale process entering its final stage.

Also on Monday, Aviva confirmed that its joint venture in China will be retained, given the scale of the market, "excellent" relationship with its partner China Oil & Food Corp and the high growth prospects.

BT Group was down 0.9% after Barclays downgraded the telecommunications firm to Underweight from Equal Weight.

The bank believes a dividend cut from BT is a possibility and that it will struggle to meet financial 2021 earnings guidance.

In the FTSE 250, Diploma was up 3.5% after the technical products supplier upped its final payout for financial 2019 after reporting a "strong double-digit growth in revenues and earnings".

The London-headquartered company, which supplies seals, filters, specialised wiring and fastners, also said its remains confident of making further progress in the current financial 2020 as moderately lower underlying growth will be offset by a strong contribution from acquisitions. Diploma posted a 15% rise in pretax profit for the year ended September 30 to GBP83.5 million from GBP72.7 million a year ago.

Diploma recommended a 15% increase in its final dividend to 20.5 pence per share, with the total annual payout up 14% to 29.0p from 25.5p last year.

Elsewhere, Consort Medical was up 43% at 1,040p after the pharmaceutical company agreed to a GBP505 million acquisition offer from Swedish peer Recipharm.

Under the offer, a unit of Recipharm will pay 1,010 pence in cash for each Consort share, representing a premium of 39% to Consort's closing stock price of 726p on Friday. The proposed deal implies an enterprise value of GBP627 million for Consort. Recipharm may reduce its acquisition consideration if any dividend or other distribution is made by the Hemel Hempstead-based company, Consort said.

The pound was quoted at USD1.2965 at midday, up from USD1.2901 at the London equities close Friday.

With just under a month to go until the UK general election, UK Prime Minister Boris Johnson pitched to cut employers' National Insurance as part of a range of tax cuts as he seeks to get the business community back on side.

In a major election pledge, the Conservative Party said a Tory government would cut business rates, launching a fundamental review at their first UK budget.

The Conservatives said they will increase the employment allowance from GBP3,000 to GBP4,000, providing a cut in National Insurance of up to GBP1,000 for more than half a million businesses.

Under the plans, the R&D tax credit rate will increase from 12% to 13%, which the Tories say will boost manufacturing and the professional, scientific and technical services sectors in particular.

"At the moment it seems like the market is pricing in a Tory victory thus investors are hoping that increased positions in UK stocks will put them in a good place to enjoy a bounce on the election result. However, a lot can change in politics in three weeks so the markets are likely to remain volatile right up to the big vote," said AJ Bell's Russ Mould.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

London market Midday is available to subscribers as an email newsletter. Contact info@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2017 08:10

Consort Medical splutters as BAT stubs out Voke programme

(ShareCast News) - British American Tobacco has terminated an agreement with Consort Medical over the manufacture of nicotine inhalers for its Voke development programme. Consort, which said it was in "constructive dialogue" with BAT's Nicovations arm and product developer Kind Consumer over the fut

Read more
6 Dec 2016 08:18

Consort Medical posts good growth in first half

(ShareCast News) - Single source drug and delivery device company Consort Medical announced its interim results for the six months to 31 October on Tuesday. The London-listed firm said group revenue increased to £144.9m from £135.5m, representing underlying growth of 2.0% and reported growth of 6.9%

Read more
25 Nov 2016 09:07

Consort Medical appoints new CFO

(ShareCast News) - Consort Medical, a global provider of manufacturing solutions for drugs, announced that it has appointed Paul Hayes as group Finance Director of the Vitec Group. Hayes is taking over the position of chief financial officer from Richard Cotton as well joining the board as executive

Read more
27 Oct 2016 07:45

Consort Medical Welcomes Cimzia Autoclicks Launch On NHS

Read more
14 Oct 2016 12:23

Consort Medical's Bespak inks new agreement

(ShareCast News) - Consort medical, a global single source drug and Delivery device company (CDMO), has announced that its Bespak division has entered into an agreement with a biopharmaceutical company. Bespak manufactures drug delivery devices for pharmaceutical partner companies including respirat

Read more
19 Sep 2016 09:07

Consort Notes European Nod For Bespak Technology-Using Product

Read more
7 Sep 2016 08:43

Consort Medical signs agreement with AstraZeneca

(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be

Read more
7 Sep 2016 07:03

Consort Medical Sees Little Brexit Impact; Signs Deal With AstraZeneca

Read more
23 Jun 2016 15:19

Director dealings: Derwent London CEO sells just ahead of Brexit vote

(ShareCast News) - Derwent London chief executive John Burns has sold £1.5m of the FTSE 250 real estate investor's shares in the week just before the EU referendum which could seriously lift or undermine the company's shares. In Wednesday's sale, which comes two days before results for Britain's ref

Read more
17 Jun 2016 09:29

Numis places Consort Medical 'under review'

(ShareCast News) - Consort Medical's shares were put 'under review' by Numis after the company reported its full year results. The pharmaceutical device frim on Thursday reported full year earnings before interest and tax rose 47.6% to £37m as revenues gained 49.8% to £276.9m, driven by a strong per

Read more
16 Jun 2016 14:52

Consort Medical's annual revenues rise as a product launch is delayed

(ShareCast News) - Consort Medical, a pharmaceutical device company, revealed higher full year profits on Thursday due to organic growth and an acquisition. Revenues rose 49.8% to £276.9m from £184.8m the previous financial year. Bespak, the company's drug device manufacturing subsidiary, continued

Read more
16 Jun 2016 07:37

Consort Medical Profit Doubles As Progress Made On DEV610 Programme

Read more
9 Jun 2016 15:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Apr 2016 08:32

BROKER RATINGS SUMMARY: Liberum Upgrades Babcock To Hold From Sell

Read more
22 Feb 2016 16:51

Consort Medical agrees partnership and invests in Precision Ocular

(ShareCast News) - Consort Medical has made a £3.3m equity investment for a 13.7% stake in retinal therapeutics specialist Precision Ocular and agreed a development and manufacturing partnership. London-based Precision Ocular has developed retinal treatments that are designed to access specific sma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.